The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

The drugmaker said it has started selling higher doses of the injectable treatment for $349 a month to patients paying the ...

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

The Danish anti-obesity drugmaker slashed prices for its Wegovy and Ozempic treatments. Shares fell more than 1%. ↘️ [XPeng ...

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...